RapidPulse Launches With $15 Million Series A Financing for Ischemic Stroke Therapy
June 23, 2021 09:00 ET
|
RapidPulse, Inc
MIAMI, June 23, 2021 (GLOBE NEWSWIRE) -- RapidPulse, Inc., a privately-held medical device company developing a novel aspiration system to treat ischemic stroke, today announced the closing of a $15...
Algernon Pharmaceuticals Targets First Human Study of its Psychedelic Drug DMT Stroke Program for Q4, 2021
June 17, 2021 07:00 ET
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia, June 17, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) is pleased to announce that all...
The Worldwide Neurovascular Devices/Interventional Neurology Industry is Expected to Reach $3.8 Billion by 2026 at a CAGR of 8.6% from 2021
June 10, 2021 05:53 ET
|
Research and Markets
Dublin, June 10, 2021 (GLOBE NEWSWIRE) -- The "Global Neurovascular Devices/Interventional Neurology Market by Product (Embolization (Coil, Flow Diverter), Stents, Balloon Occlusion Devices, Clot...
Algernon Pharmaceuticals Highlights New Animal Study Showing Effectiveness of Psychedelic Drug DMT in Treatment of Stroke
May 27, 2021 07:00 ET
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia, May 27, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) is pleased to highlight an...
Algernon Pharmaceuticals Receives Positive Feedback from U.S. FDA for Psychedelic Drug DMT Clinical Research Program for Stroke
May 17, 2021 07:00 ET
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia, May 17, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) announces it has received...
Insights on the Intracranial Aneurysm Global Market to 2025 - Competitive Analysis and the Impact of COVID-19
April 21, 2021 06:33 ET
|
Research and Markets
Dublin, April 21, 2021 (GLOBE NEWSWIRE) -- The "Global Intracranial Aneurysm Market (2020-2025) by Type, Condition, Treatment Type, End-User, Geography, Competitive Analysis and the Impact of...
NovaSignal Launches Platform To Transform Cerebral Blood Flow Measurement
April 14, 2021 09:06 ET
|
NovaSignal Corporation
LOS ANGELES, April 14, 2021 (GLOBE NEWSWIRE) -- NovaSignal Corp., a medical technology and data company specializing in assessing cerebral blood flow, today launched the NovaGuide™ 2 Platform that...
Algernon Pharmaceuticals Announces Appointment of Global Expert Dr. Steven L. Wolf for DMT Stroke Program
April 06, 2021 08:00 ET
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia, April 06, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical...
Algernon Pharmaceuticals Announces its Addition to the Market's First Psychedelic Stock Index ETF
March 29, 2021 07:02 ET
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia., March 29, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage...
Algernon Pharmaceuticals Submits U.S. FDA Pre-IND Meeting Request for Psychedelic Drug DMT Clinical Research Program for Stroke
March 17, 2021 07:00 ET
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia, March 17, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”), a clinical stage...